XERS Q4 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+42.8% YoY

Gross Profit

$67M77.8% margin

Operating Income

$17M19.5% margin

Net Income

$11M12.9% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+15.4%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$20M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$384M

Total Liabilities

$370M

Stockholders' Equity

$14M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$60M	+42.8%
Gross Profit	$67M	$51M	+31.8%
Operating Income	$17M	$2M	+899.0%
Net Income	$11M	-$5M	+316.7%

Revenue Segments

Product

$83M86%

Keveyis

$13M13%

Product, Other

$651,0001%